Press Releases Hansae Yes24 Holdings Co., Ltd

Equities

A016450

KR7016450009

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-07-11 pm EDT			5-day change	1st Jan Change
4,725 ^KRW	+0.53%		+1.83%	-3.57%

May. 16	Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 20	Hansae Yes24 Holdings Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hansa Biopharma: increase in number of shares and votes	Jul. 01	AQ
Hansa Biopharma: increase in number of shares and votes	Jun. 28	AQ
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)	Jun. 27	AQ
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial	May. 31	AQ
Notice to Annual General Meeting in Hansa Biopharma AB (publ)	May. 27	AQ
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting	May. 21	AQ
Correction, Hansa Biopharma, increase in number of shares and votes	May. 06	AQ
Hansa Biopharma: increase in number of shares and votes	May. 03	AQ
Hansa Biopharma interim report January-March 2024	Apr. 18	AQ
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	Apr. 11	AQ
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	Apr. 02	AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	Mar. 21	AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	Feb. 22	AQ
Hansa Biopharma Year-end report January-December 2023	Feb. 02	AQ
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	Jan. 06	AQ
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	Dec. 15	AQ
Hansa Biopharma Nomination Committee formed	Dec. 13	AQ
Hansa Biopharma - Imlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 Trial in Guillain-Barre Syndrome	Dec. 08	AQ
Hansa Biopharma plans restructuring to strengthen long-term competitiveness and advance key deliverables	Dec. 05	AQ
Hansa Biopharma announces planned departure of Chief Financial Officer Donato Spota	Nov. 27	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Hansae Yes24 Holdings Co., Ltd

Equities

A016450

KR7016450009

Press Releases

Filters